Literature DB >> 27043317

Evaluation of a Carbonic Anhydrase IX-Targeted Near-Infrared Dye for Fluorescence-Guided Surgery of Hypoxic Tumors.

Peng-Cheng Lv1, Jyoti Roy1, Karson S Putt1, Philip S Low1.   

Abstract

Proof-of-principle studies in ovarian, lung, and brain cancer patients have shown that fluorescence-guided surgery can enable removal of otherwise undetectable malignant lesions, decrease the number of cancer-positive margins, and permit identification of disease-containing lymph nodes that would have normally evaded resection. Unfortunately, the current arsenal of tumor-targeted fluorescent dyes does not permit identification of all cancers, raising the need to design new tumor-specific fluorescent dyes to illuminate the currently undetectable cancers. In an effort to design a more universal fluorescent cancer imaging agent, we have undertaken to synthesize a fluorophore that could label all hypoxic regions of tumors. We report here the synthesis, in vitro binding, and in vivo imaging of a near-infrared (NIR) fluorescent dye that is targeted to carbonic anhydrase IX (CA IX), i.e., a widely accepted marker of hypoxic tissues. The low molecular weight NIR probe, named Hypoxyfluor, is shown to bind CA IX with high affinity and accumulate rapidly and selectively in CA IX positive tumors. Because nearly all human cancers contain hypoxic regions that express CA IX abundantly, this NIR probe should facilitate surgical resection of a wide variety of solid tumors.

Entities:  

Keywords:  CA IX; carbonic anhydrase IX; fluorescence-guided surgery; hypoxia

Mesh:

Substances:

Year:  2016        PMID: 27043317      PMCID: PMC5358012          DOI: 10.1021/acs.molpharmaceut.6b00065

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  51 in total

1.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

2.  Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.

Authors:  S K Chia; C C Wykoff; P H Watson; C Han; R D Leek; J Pastorek; K C Gatter; P Ratcliffe; A L Harris
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

3.  Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis.

Authors:  Joonas A Haapasalo; Kristiina M Nordfors; Mika Hilvo; Immo J Rantala; Ylermi Soini; Anna-Kaisa Parkkila; Silvia Pastoreková; Jaromir Pastorek; Seppo M Parkkila; Hannu K Haapasalo
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

4.  Evaluation of a cholecystokinin 2 receptor-targeted near-infrared dye for fluorescence-guided surgery of cancer.

Authors:  Charity Wayua; Philip S Low
Journal:  Mol Pharm       Date:  2013-12-16       Impact factor: 4.939

5.  High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer.

Authors:  M Ilie; N M Mazure; V Hofman; R E Ammadi; C Ortholan; C Bonnetaud; K Havet; N Venissac; B Mograbi; J Mouroux; J Pouysségur; P Hofman
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

Review 6.  Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases.

Authors:  Narges K Tafreshi; Mark C Lloyd; Marilyn M Bui; Robert J Gillies; David L Morse
Journal:  Subcell Biochem       Date:  2014

7.  Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation.

Authors:  J Saarnio; S Parkkila; A K Parkkila; K Haukipuro; S Pastoreková; J Pastorek; M I Kairaluoma; T J Karttunen
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

8.  The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.

Authors:  Harlinde De Schutter; Willy Landuyt; Erik Verbeken; Laurence Goethals; Robert Hermans; Sandra Nuyts
Journal:  BMC Cancer       Date:  2005-04-25       Impact factor: 4.430

Review 9.  Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia.

Authors:  Shaliny Ramachandran; Jonathan Ient; Eva-Leonne Göttgens; Adam J Krieg; Ester M Hammond
Journal:  Genes (Basel)       Date:  2015-09-25       Impact factor: 4.096

10.  GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON.

Authors:  P J Hoskin; A Sibtain; F M Daley; G D Wilson
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more
  12 in total

1.  A METHYLATION-TO-EXPRESSION FEATURE MODEL FOR GENERATING ACCURATE PROGNOSTIC RISK SCORES AND IDENTIFYING DISEASE TARGETS IN CLEAR CELL KIDNEY CANCER.

Authors:  Jeffrey A Thompson; Carmen J Marsit
Journal:  Pac Symp Biocomput       Date:  2017

2.  CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer.

Authors:  Zhaoxian Wang; Samaresh Sau; Hashem O Alsaab; Arun K Iyer
Journal:  Nanomedicine       Date:  2018-04-17       Impact factor: 5.307

3.  pH-Sensitive Multiligand Gold Nanoplatform Targeting Carbonic Anhydrase IX Enhances the Delivery of Doxorubicin to Hypoxic Tumor Spheroids and Overcomes the Hypoxia-Induced Chemoresistance.

Authors:  Ahmed M Shabana; Utpal K Mondal; Md Raqibul Alam; Taylor Spoon; Codee Alicia Ross; Muniswamy Madesh; Claudiu T Supuran; Marc A Ilies
Journal:  ACS Appl Mater Interfaces       Date:  2018-05-15       Impact factor: 9.229

4.  Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.

Authors:  Hashem O Alsaab; Samaresh Sau; Rami M Alzhrani; Vino T Cheriyan; Lisa A Polin; Ulka Vaishampayan; Arun K Rishi; Arun K Iyer
Journal:  Biomaterials       Date:  2018-08-30       Impact factor: 12.479

Review 5.  New Developments in Carbonic Anhydrase IX-Targeted Fluorescence and Nuclear Imaging Agents.

Authors:  Kuo-Ting Chen; Yann Seimbille
Journal:  Int J Mol Sci       Date:  2022-05-30       Impact factor: 6.208

6.  Picomolar fluorescent probes for compound affinity determination to carbonic anhydrase IX expressed in live cancer cells.

Authors:  Jurgita Matulienė; Gediminas Žvinys; Vytautas Petrauskas; Agnė Kvietkauskaitė; Audrius Zakšauskas; Kirill Shubin; Asta Zubrienė; Lina Baranauskienė; Lina Kačenauskaitė; Sergei Kopanchuk; Santa Veiksina; Vaida Paketurytė-Latvė; Joana Smirnovienė; Vaida Juozapaitienė; Aurelija Mickevičiūtė; Vilma Michailovienė; Jelena Jachno; Dovilė Stravinskienė; Aistė Sližienė; Agnė Petrošiūtė; Holger M Becker; Justina Kazokaitė-Adomaitienė; Ala Yaromina; Edita Čapkauskaitė; Ago Rinken; Virginija Dudutienė; Ludwig J Dubois; Daumantas Matulis
Journal:  Sci Rep       Date:  2022-10-21       Impact factor: 4.996

7.  Evaluation of Nonpeptidic Ligand Conjugates for SPECT Imaging of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers.

Authors:  Peng-Cheng Lv; Karson S Putt; Philip S Low
Journal:  Bioconjug Chem       Date:  2016-07-07       Impact factor: 4.774

Review 8.  Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging.

Authors:  Nirilanto Ramamonjisoa; Ellen Ackerstaff
Journal:  Front Oncol       Date:  2017-01-31       Impact factor: 6.244

Review 9.  Combination of Fluorescence-Guided Surgery With Photodynamic Therapy for the Treatment of Cancer.

Authors:  Jun He; Leping Yang; Wenjun Yi; Wentao Fan; Yu Wen; Xiongying Miao; Li Xiong
Journal:  Mol Imaging       Date:  2017 Jan-Dec       Impact factor: 4.488

10.  Cell-surface marker discovery for lung cancer.

Authors:  Allison S Cohen; Farah K Khalil; Eric A Welsh; Matthew B Schabath; Steven A Enkemann; Andrea Davis; Jun-Min Zhou; David C Boulware; Jongphil Kim; Eric B Haura; David L Morse
Journal:  Oncotarget       Date:  2017-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.